China Pharma Holdings (CPHI) Stock Price, News & Analysis

China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty pharmaceutical company engaged in the development, manufacture, and marketing of pharmaceutical products for human use. The company focuses on conditions with high incidence and high mortality rates in the People’s Republic of China, including cardiovascular, central nervous system (CNS), infectious, and digestive diseases. Through its operations in pharmaceutical preparation manufacturing, China Pharma participates in the broader manufacturing sector while concentrating on human health.

According to available information, China Pharma’s product portfolio covers multiple dosage forms. The company manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its product line has included items such as cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, and gastrodin injection, among others. These products are aimed at addressing a variety of medical conditions prevalent in China.

China Pharma describes its business model as cost-effective and driven by market demand. Its operations are supported by GMP-certified product lines that cover major dosage forms. The company states that it has a broad and expanding nationwide distribution network across major cities and provinces in China, which supports the commercialization of its pharmaceutical products. This network has also been referenced in connection with the planned promotion of new medical devices.

The company operates through its wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. (“Helpson”), which is based in Haikou City, Hainan Province, China. Helpson is described as a fully integrated specialty pharmaceuticals subsidiary, involved in activities such as product development, manufacturing, and commercialization. Various company announcements also indicate that Helpson is the contractual counterparty for technology transfer agreements and is the registrant for certain medical products with Chinese regulatory authorities.

Therapeutic Focus Areas

China Pharma’s stated focus on cardiovascular, CNS, infectious, and digestive diseases reflects its emphasis on conditions that are widespread in China. For example, the company has highlighted its candesartan tablets as a hypertension product. Candesartan is described in company communications as an angiotensin II antagonist suitable for primary hypertension. The company has reported that its candesartan tablets passed the quality and efficacy consistency evaluation of generic drugs conducted by the National Medical Products Administration (NMPA) of China, which is intended to confirm that approved generic drugs reach the same level of quality and efficacy as the innovator drug.

In addition to cardiovascular-related products, China Pharma has referenced modern Traditional Chinese Medicine (TCM) anti-virus products such as andrographolide, as well as cold medicines that include naproxen sodium and pseudoephedrine hydrochloride sustained release tablets (under the brand name Pusen OK). The company has also mentioned antibiotics such as roxithromycin and cefaclor in the context of demand related to public health events in China.

Medical Devices and New Product Lines

Beyond traditional pharmaceuticals, China Pharma has described efforts to develop and commercialize medical devices and related health products. The company announced a Dry Eye Disease (DED) therapeutic device that has undergone third-party testing and is under patent protection. According to company disclosures, this device is embedded with an ophthalmic oxygen-enriched atomization therapeutic instrument. The technology is described as spraying tiny oxygen-rich droplets evenly into patients’ eyes to increase moisture and oxygen supply on the eye surface and improve the quality and stability of tear fluid. The company characterizes this as a form of physical therapy that aims to avoid side effects associated with drugs while acting directly on the eyes.

China Pharma has also reported the launch of an N95 medical protective mask. The N95 mask is described as a medical-level protective mask used to filter particles and block droplets, blood, body fluids, and secretions in the air under medical work environments. The registration certificate for this mask was issued to Helpson by the Hainan Medical Products Administration, and the company has presented this as part of its response to public health needs in China.

Regulatory and Quality Milestones

The company’s communications reference several regulatory milestones in China. For example, the candesartan tablets’ passage of the generic drug quality and efficacy consistency evaluation by the NMPA is highlighted as evidence that the product can replace the innovator drug in clinical practice and may qualify to participate in China’s national centralized procurement. The Dry Eye Disease therapeutic device is reported to have passed third-party testing and to be preparing for market launch application to the NMPA.

China Pharma has also noted that several of its drugs were listed in the “Catalogue of Medicines for People Infected with COVID-19 (First Edition)” published by People’s Daily. The company specifically mentions its modern TCM anti-virus product andrographolide, its cold medicine containing naproxen sodium and pseudoephedrine hydrochloride sustained release tablets, and indicates that demand for antibiotics such as roxithromycin and cefaclor, as well as for masks, increased in connection with changes in epidemic control policies in China.

Corporate Structure, Exchange Listing, and Governance

China Pharma Holdings, Inc. is incorporated in Nevada and its common stock is listed on the NYSE American under the trading symbol CPHI. SEC filings identify the company’s common stock as registered under Section 12(b) of the Securities Exchange Act, with CPHI as the trading symbol on the NYSE American exchange. The company holds annual meetings of stockholders, as reflected in its proxy statements and Form 8-K filings, where matters such as the election of independent directors, authorization of reverse stock splits, and amendments to long-term incentive plans are submitted for stockholder approval.

Several Form 8-K filings describe stockholder votes to authorize reverse stock splits at ratios up to 1:20 and subsequent board decisions to implement specific reverse stock split ratios. These actions have been taken while maintaining the listing of the company’s common stock on the NYSE American under the CPHI symbol. The filings indicate that reverse stock splits are structured so that all stockholders are affected uniformly, with fractional shares rounded up to the next whole number.

Technology Transfers and Intellectual Property

China Pharma, through Helpson, has entered into technology transfer agreements related to pharmaceutical patents. In one agreement, Helpson agreed to acquire an invention patent for ipragliflozin tablets and their method of preparation, with the transferor or a designated third party providing technical services such as product research and development, preparation of registration materials, and registration applications. In another agreement, Helpson agreed to acquire an invention patent for a captopril microcapsule and its method of preparation, with similar technical service obligations from the transferor or designated third party.

In both cases, the transfer price is to be paid in the form of restricted shares of China Pharma’s common stock, issued under Regulation S to non-U.S. persons through offshore transactions. These agreements illustrate the company’s use of equity as consideration in acquiring pharmaceutical technology and intellectual property intended to support future product development.

Distribution Network and Market Presence in China

China Pharma states that it has a broad and expanding nationwide distribution network across major cities and provinces in China. The company has indicated that it has established sales channels in more than 30 provincial and municipal hospitals, as well as over-the-counter (OTC) markets in China over a period of more than 20 years. This network is presented as a key support for the launch and promotion of products such as the Dry Eye Disease therapeutic device and other pharmaceutical offerings.

The company’s communications also reference the scale of certain disease areas in China, such as the large number of cardiovascular disease and hypertension patients and the significant population affected by dry eye disease. These references are used by the company to contextualize the potential demand for its products, including candesartan tablets and the Dry Eye Disease therapeutic device.

Capital Markets and Financing Activities

China Pharma has engaged in various capital markets activities, including convertible note financing and equity offerings. The company reported the issuance of a Convertible Promissory Note with a principal amount of $5,250,000 and later announced the completion of all redemptions under this note, emphasizing its efforts to meet financial commitments. The company has also filed a prospectus supplement under a shelf registration statement on Form S-3 to allow for an at-the-market equity offering of common stock up to an aggregate offering price of $600,000, pursuant to a securities purchase agreement with an investor.

In addition, the company has used unregistered sales of equity securities as consideration in technology transfer transactions, as described in its Form 8-K filings. These transactions involve the planned issuance of restricted shares of common stock to non-U.S. persons in offshore transactions under Regulation S.

Reverse Stock Splits

China Pharma has undertaken multiple reverse stock splits of its common stock. Company announcements describe reverse stock splits at ratios such as 1-for-10 and 1-for-5, with trading on a split-adjusted basis on the NYSE American under the CPHI symbol. The company has also obtained stockholder approval for the board to effect a reverse stock split at a ratio of up to 1:20, with discretion for the board to determine if and when to implement such a split. In each case, the company has stated that the reverse stock split affects all stockholders uniformly and does not alter any stockholder’s percentage interest in the outstanding common stock, except for adjustments related to the treatment of fractional shares.